CX Institutional’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.46M | Sell |
6,874
-492
| -7% | -$96.6K | 0.04% | 289 |
|
|
2026
Q1 | $1.44M | Buy |
7,366
+666
| +10% | +$129K | 0.04% | 290 |
|
|
2025
Q4 | $1.16M | Sell |
6,700
-1,203
| -15% | -$219K | 0.03% | 265 |
|
|
2025
Q3 | $1.51M | Buy |
7,903
+40
| +0.5% | +$7.1K | 0.05% | 242 |
|
|
2025
Q2 | $1.41M | Sell |
7,863
-1,636
| -17% | -$284K | 0.05% | 224 |
|
|
2025
Q1 | $1.61M | Buy |
9,499
+366
| +4% | +$60.1K | 0.06% | 213 |
|
|
2024
Q4 | $1.38M | Sell |
9,133
-1,205
| -12% | -$187K | 0.05% | 217 |
|
|
2024
Q3 | $1.6M | Buy |
10,338
+537
| +5% | +$80.2K | 0.07% | 215 |
|
|
2024
Q2 | $1.34M | Buy |
9,801
+626
| +7% | +$85.7K | 0.06% | 233 |
|
|
2024
Q1 | $1.22M | Buy |
9,175
+6,461
| +238% | +$838K | 0.06% | 251 |
|
|
2023
Q4 | $374K | Buy |
2,714
+50
| +2% | +$6.57K | 0.02% | 363 |
|
|
2023
Q3 | $325K | Sell |
2,664
-288
| -10% | -$38.4K | 0.02% | 386 |
|
|
2023
Q2 | $415K | Buy |
2,952
+251
| +9% | +$34.6K | 0.02% | 372 |
|
|
2023
Q1 | $385K | Sell |
2,701
-65
| -2% | -$9.3K | 0.02% | 377 |
|
|
2022
Q4 | $433K | Buy |
2,766
+238
| +9% | +$34.2K | 0.03% | 386 |
|
|
2022
Q3 | $310K | Buy |
2,528
+82
| +3% | +$10.8K | 0.02% | 388 |
|
|
2022
Q2 | $325K | Sell |
2,446
-78
| -3% | -$10.6K | 0.02% | 377 |
|
|
2022
Q1 | $345K | Buy |
2,524
+45
| +2% | +$6.27K | 0.03% | 298 |
|
|
2021
Q4 | $429K | Buy |
2,479
+30
| +1% | +$4.57K | 0.03% | 257 |
|
|
2021
Q3 | $356K | Buy |
2,449
+5
| +0.2% | +$732 | 0.03% | 295 |
|
|
2021
Q2 | $323K | Buy |
2,444
+46
| +2% | +$6.02K | 0.03% | 291 |
|
|
2021
Q1 | $308K | Buy |
2,398
+31
| +1% | +$3.82K | 0.03% | 261 |
|
|
2020
Q4 | $282K | Buy |
2,367
+34
| +1% | +$4.14K | 0.03% | 272 |
|
|
2020
Q3 | $267K | Sell |
2,333
-51
| -2% | -$6.03K | 0.03% | 241 |
|
|
2020
Q2 | $272K | Sell |
2,384
-64
| -3% | -$6.79K | 0.04% | 226 |
|
|
2020
Q1 | $197K | Buy |
2,448
+209
| +9% | +$21.6K | 0.03% | 230 |
|
|
2019
Q4 | $239K | Sell |
2,239
-10,144
| -82% | -$1.06M | 0.04% | 186 |
|
|
2019
Q3 | $1.32M | Buy |
+12,383
| New | +$1.27M | 0.21% | 103 |
|
|
2019
Q2 | – | Sell |
-2,252
| Closed | -$202K | – | 957 |
|
|
2019
Q1 | $202K | Buy |
2,252
+52
| +2% | +$4.51K | 0.04% | 214 |
|
|
2018
Q4 | $183K | Buy |
+2,200
| New | +$206K | 0.04% | 173 |
|
Other funds holding DGX
EIG
CX Institutional's DGX Position: Q2 2026 in Review
CX Institutional reduced its Quest Diagnostics (DGX) stake by 6.7% in Q2 2026, selling an estimated $96.6K and leaving 6,874 shares worth $1.46M. The position accounts for 0.04% of the portfolio, ranked #289.
CX Institutional first reported a position in DGX in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.61M in Q1 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- CX Institutional held 6,874 shares of Quest Diagnostics worth $1.46M as of Q2 2026.
- CX Institutional sold 492 Quest Diagnostics shares in Q2 2026, an estimated $96.6K.
- Quest Diagnostics made up 0.04% of CX Institutional's portfolio in Q2 2026, its #289 holding.
- CX Institutional first reported a position in Quest Diagnostics in Q4 2018 and has held it in 30 quarters since.
- CX Institutional's Quest Diagnostics position peaked at $1.61M in Q1 2025.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.